Delcath Systems Presents Data Regarding Its Clinical Development Programs At European Society For Medical Oncology Congress 2026; Presents Publication Of Analysis Of Percutaneous Hepatic Perfusion With Melphalan Using CHEMOSAT Hepatic Delivery Systems
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced presentations related to its clinical development
Delcath shared new research about its liver cancer treatment system. When a company presents fresh data, investors watch to see if the science is working as hoped.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.